Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SAGE-217 for severe postpartum depression has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Postpartum Depression

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Depression, Postpartum | Phase 3 | Status: COMPLETED | Results posted: 2023-06-22